NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief ...

CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA's strong prescription uptake continues: Q2 2024 CAPLYTA total prescriptions increased 36%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance raised to $650 to $680 million Announced positive Phase 3 results from Study 501 and Study 502 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disord ...

CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA's strong prescription uptake continues: Q2 2024 CAPLYTA total prescriptions increased 36%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance raised to $650 to $680 million Announced positive Phase 3 results from Study 501 and Study 502 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disord ...

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024. To attend the live conference ca ...

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024. To attend the live conference c ...

Shares of Intra-Cellular Therapies (ITCI) have gained 3.6% over the past four weeks to close the last trading session at $71.56, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.13 indicates a potential upside of 30.1%.The mean estimate comprises 15 short-term price targets with a standard deviation of $14.69. While the lowest estimate of $65 indicates a 9.2% decline from the ...

文章核心观点 - Intra-Cellular是一家专注于神经精神疾病和神经系统疾病的商业阶段生物技术公司[1] - 公司主要产品Caplyta(lumateperone 42mg)已获批用于治疗成人精神分裂症和双相抑郁症[2][3] - Caplyta销售额持续增长,2023年第一季度同比增长53%,处方量增长85%[4] - 公司正在评估Caplyta用于治疗其他适应症,如抑郁症,预计将在2024年下半年提交补充新药申请[6][7][8] - 公司还在开发其他神经系统疾病和癌症领域的候选药物,现金储备充足[10][11][12] - 但公司依赖单一产品的风险较高,面临监管环境趋严和竞争加剧的挑战[13][14][15] 公司概况 - Intra-Cellular是一家专注于神经精神疾病和神经系统疾病的商业阶段生物技术公司[1] - 公司主要产品Caplyta(lumateperone 42mg)已获批用于治疗成人精神分裂症和双相抑郁症[2][3] - 公司正在评估Caplyta用于治疗其他适应症,如抑郁症,预计将在2024年下半年提交补充新药申请[6][7][8] - 公司还在开发其他神经系统疾病和癌症领域的候选药物,现金储备充足[10][11][12] 产品表现 - Caplyta销售额持续增长,2023年第一季度同比增长53%,处方量增长85%[4] - 公司预计Caplyta未来销售将进一步提高[5] 挑战与风险 - 公司依赖单一产品的风险较高[13] - 面临监管环境趋严和竞争加剧的挑战[14][15]

Intra-Cellular Therapies (ITCI) announced positive top-line results from Study 502, the second late-stage study that evaluated lumateperone 42 mg for the treatment of major depressive disorder (MDD).The second phase III study evaluating lumateperone 42 mg, given once daily as an adjunctive therapy to antidepressants for MDD, met the primary endpoint. A statistically significant and clinically meaningful reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score was observed compared with ...

Intra-Cellular Therapies (ITCI) shares rallied 9.6% in the last trading session to close at $75.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.4% gain over the past four weeks.The sudden soaring of the stock price was observed after the company announced achieving statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of the second late-stage stu ...